Partner Marta Delsignore discusses how a recent case, Dodocase VR Inc. v. MerchSource LLC, demonstrates the impact forum selection clauses in patent license agreements can have on the availability of patent challenges in the PTAB.
Read the full article.
Related Content
- AlertMay 22, 2024
The Appeals Review Panel’s In Re Xencor Decision: The USPTO Provides Its Position on Written Description and Means-Plus-Function Claims
- AlertMarch 12, 2024
USPTO’s New Guidance on AI-Assisted Inventions: The Impact on the Use of AI in the Life Sciences
- AlertFebruary 13, 2024
USPTO Issues New Guidance on Patenting AI-Assisted Inventions
- InsightJanuary 16, 2024
What’s Next for AI? Six Areas to Watch in 2024
- InsightNovember 30, 2023
How To Reduce the Risk of Copyright Infringement When Using Generative AI To Write Code
- InsightOctober 31, 2023
Coding with AI in an Open-Source World
- AlertAugust 30, 2023
In re Cellect: Federal Circuit Opens New Path for Double Patenting Challenges
- AlertAugust 29, 2023
Biden Executive Order Puts Focus on Domestic Manufacturing of Inventions Created Using Federal Funding
- Speaking EngagementsJuly 24, 2024 | 2:00 PM - 3:15 PM ET
ACS Webinar - Avoiding IP Own Goals in Drug Discovery: Best Practices for Obtaining (and Keeping) Your IP
- Awards and Rankings20 June 2024
Best Lawyers in France 2025 Recognizes 16 Paris Lawyers
- Press ReleaseJune 13, 2024
Rapport Therapeutics Completes $174.4 Millon Initial Public Offering and Concurrent Private Placement
- Awards and RankingsJune 11, 2024
Managing IP Names 22 Goodwin Lawyers IP Stars 2024
- Awards and RankingsJune 6, 2024
Chambers USA 2024 Recognizes Goodwin Practices and Lawyers for Exceptional Client Service
- Press ReleaseMay 29, 2024
Akili Interactive to Be Acquired by Virtual Therapeutics
- Awards and RankingsMay 24, 2024
Neel Chatterjee and Brett Schuman Named Top IP Lawyers by Daily Journal
- Press ReleaseMay 24, 2024
Aktis Oncology and Eli Lilly Collaborate on Discovery and Development of Novel Anticancer Radiopharmaceuticals; Aktis To Receive $60 Million Upfront and up to an Additional $1.1 Billion in Potential Milestones